Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-14-060551
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-10-01 16:31:48
Reporting Period:
2014-09-29
Filing Date:
2014-10-01
Accepted Time:
2014-10-01 16:31:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1157602 Vitae Pharmaceuticals Inc VTAE Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1239242 E Bryan Roberts C/o Venrock
3340 Hillview Avenue
Palo Alto CA 94304
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-09-29 48,333 $0.00 48,333 No 4 C Indirect See Footnote
Common Stock Acquisiton 2014-09-29 214,820 $0.00 214,820 No 4 C Indirect See Footnote
Common Stock Acquisiton 2014-09-29 5,367 $0.00 5,367 No 4 C Indirect See Footnote
Common Stock Acquisiton 2014-09-29 227,117 $0.00 275,450 No 4 C Indirect See Footnote
Common Stock Acquisiton 2014-09-29 1,009,414 $0.00 1,224,234 No 4 C Indirect See Footnote
Common Stock Acquisiton 2014-09-29 25,233 $0.00 30,600 No 4 C Indirect See Footnote
Common Stock Acquisiton 2014-09-29 9,285 $0.00 284,735 No 4 C Indirect See Footnote
Common Stock Acquisiton 2014-09-29 41,270 $0.00 1,265,504 No 4 C Indirect See Footnote
Common Stock Acquisiton 2014-09-29 1,031 $0.00 31,631 No 4 C Indirect See Footnote
Common Stock Acquisiton 2014-09-29 139,019 $8.00 423,754 No 4 P Indirect See Footnote
Common Stock Acquisiton 2014-09-29 617,868 $8.00 1,883,372 No 4 P Indirect See Footnote
Common Stock Acquisiton 2014-09-29 15,446 $8.00 47,077 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A-2 Preferred Stock Disposition 2014-09-29 32,086 $0.00 48,333 $0.00
Common Stock Series A-2 Preferred Stock Disposition 2014-09-29 142,607 $0.00 214,820 $0.00
Common Stock Series A-2 Preferred Stock Disposition 2014-09-29 3,563 $0.00 5,367 $0.00
Common Stock Series B Preferred Stock Disposition 2014-09-29 227,117 $0.00 227,117 $0.00
Common Stock Series B Preferred Stock Disposition 2014-09-29 1,009,414 $0.00 1,009,414 $0.00
Common Stock Series B Preferred Stock Disposition 2014-09-29 25,233 $0.00 25,233 $0.00
Common Stock Series C Preferred Stock Disposition 2014-09-29 9,285 $0.00 9,285 $0.00
Common Stock Series C Preferred Stock Disposition 2014-09-29 41,270 $0.00 41,270 $0.00
Common Stock Series C Preferred Stock Disposition 2014-09-29 1,031 $0.00 1,031 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Each outstanding share of Series A-2 Preferred Stock automatically converted on a 1:1.50638118 basis into the Issuer's common stock, immediately prior to the Issuer's initial public offering, for no additional consideration.
  2. The reportable securities are owned by Venrock Associates ("VA"). Dr. Roberts is a general partner of VA and disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in them.
  3. The reportable securities are owned by Venrock Associates III, L.P. ("VA III"). The sole general partner of VA III is Venrock Management III, LLC ("VM III") and it may be deemed to own these shares. Dr. Roberts is a member of VM III and disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in them.
  4. The reportable securities are owned by Venrock Entrepreneurs Fund III, L.P. ("VEF III"). The sole general partner of VEF III is VEF Management III, LLC ("VEFM III") and it may be deemed to own these shares. Dr. Roberts is a member of VEFM III and disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in them.
  5. Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted on a 1:1 basis into the Issuer's common stock, immediately prior to the Issuer's initial public offering, for no additional consideration.